Thelansis

Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Market Outlook Thelansis’s “Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook ...

  Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Market Outlook Thelansis’s “Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Overview Lung cancer remains the predominant cause of cancer-related mortality globally among both males and females. The majority of lung cancer cases are classified as non-small cell lung cancer (NSCLC), accounting for approximately 85% of cases. The most prevalent histologi...

 Advanced metastatic NSCLC has shown a significant increase in survival rates with chemotherapy compared to best supportive care alone. Subsequent advancements included improved response rates with third-generation agents such as paclitaxel, docetaxel, vinorelbine, and gemcitabine, surpassing the efficacy of second-generation treatments like ifosfamide, mitomycin, and vindesine alongside standard platinum chemotherapy in doublet regimens. Current standard practice in treating metastatic NSCLC involves targeting anaplastic lymphoma kinase (ALK) with tyrosine kinase inhibitors (TKIs), particularly for ALK-positive patients confirmed through standard FISH (Fluorescence in situ hybridization) technique or for ROS1 positive patients. Alectinib has emerged as the preferred first-line agent due to its superior progression-free survival (PFS) demonstrated in direct comparison with crizotinib. The treatment landscape for advanced NSCLC has become increasingly complex with the advent of newe...

 Non-Small Cell Lung Cancer (NSCLC) is the most common form of lung cancer. Early-stage NSCLC accounts for approximately 18% of the cases. Most of these patients are treated with curative intent and often require multimodality therapy. The 5-year overall survival (OS) ranges from 50% for stage IA disease to 15% for stage IIIA NSCLC. Several clinical trials have demonstrated improved survival with postoperative chemotherapy in selected patients who undergo complete surgical resection. Available evidence supports the use of adjuvant chemotherapy for stage II and stage IIIA, but not for stage IA NSCLC. The standard of care for patients with stage I, II and IIIA, non-small-cell lung cancer (NSCLC), is surgical resection. Following resection, patients may be offered adjuvant systemic therapy. ·        HER2 mutations and HER2 amplifications have been reported in approximately 2% to 3% and 2% to 5% of lung adenocarcinomas, respectively. Thelansis’s “Advan...